知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.028 seconds)

    Dental therapy by vesicle delivery
    2.
    发明授权
    Dental therapy by vesicle delivery 失效
    通过囊泡输送进行牙科治疗

    公开(公告)号：US4767615A

    公开(公告)日：1988-08-30

    申请号：US877862

    申请日：1986-06-24

    Applicant: W. Blair Geho ,  Joseph Jacob ,  John R. Lau

    Inventor： W. Blair Geho ,  Joseph Jacob ,  John R. Lau

    IPC: A61K8/14 ,  A61K9/127 ,  A61K9/42 ,  A61K47/48 ,  A61Q11/00 ,  A61K7/16

    CPC classification number: A61Q11/00 ,  A61K47/48084 ,  A61K47/48815 ,  A61K8/14 ,  A61K9/1271

    Abstract: A known procedure is used to prepare liposomes of bipolar lipid membrane which are permeable and hence "leak" their contents at a rate which is variable by choice. The liposome is supplied with medication or cosmetic material for the oral cavity, or specifically for the teeth and gums. The liposome is then attached to a molecule that has affinity for the hydroxyapatite. Thus, the liposome will bind to oral cavity hydroxyapatite and bathe the surrounding support surface with its contents for extended hours of service.

    Abstract translation: 使用已知的方法来制备双相脂质膜的脂质体，其是可渗透的，因此以其选择可变的速率“泄漏”其内容物。 向脂质体供应用于口腔的药物或化妆品材料，或专门用于牙齿和牙龈。 然后将脂质体连接到对羟基磷灰石具有亲和性的分子。 因此，脂质体将结合口腔羟基磷灰石，并使其周围的支撑表面与其内容物一起洗涤以延长使用时间。

    Diarrheal antitoxin
    3.
    发明授权
    Diarrheal antitoxin 失效
    腹泻抗毒素

    公开(公告)号：US4705804A

    公开(公告)日：1987-11-10

    申请号：US730830

    申请日：1985-05-06

    Applicant: W. Blair Geho ,  John R. Lau ,  Joseph Jacob

    Inventor： W. Blair Geho ,  John R. Lau ,  Joseph Jacob

    IPC: A61K9/127 ,  A61K9/42 ,  A61K31/375 ,  A61K31/34 ,  A61K9/70

    CPC classification number: A61K9/127 ,  A61K31/375 ,  Y10S514/867

    Abstract: This disclosure teaches a method of inactivating bacterial toxins, such as produced by Vibrio cholerae and Escherichia coli (hereinafter V. cholerae and E. coli) that are responsible for diarrhea in warm-blooded animals, comprising the placing of an effective dosage of ascorbic acid salts thereof, or derivatives such as the ester ascorbyl palmitate in the intestinal tract.Definition: Ascorbic acid, salts thereof, and derivatives thereof such as ascorbyl palmetate have been identified as suitable detoxifying material according to this invention. For the sake brevity, the term "ascorbic acid" hereinafter shall include the salts and esters.Diarrhea as used herein will include other toxins effecting the lower duodenum and intestines.

    Abstract translation: 本公开教导了灭活霍乱弧菌和大肠杆菌（以下称为霍乱弧菌和大肠杆菌）的细菌毒素的方法，所述细菌毒素是造成温血动物腹泻的原因，包括将有效剂量的抗坏血酸 其盐或衍生物，例如肠道中的抗坏血酸棕榈酸酯。 定义：根据本发明，抗坏血酸，其盐及其衍生物如抗坏血酸棕榈酸酯已被鉴定为合适的解毒材料。 为了简洁起见，以下术语“抗坏血酸”应包括盐和酯。 本文所用的腹泻将包括影响下十二指肠和肠道的其他毒素。

    Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
    4.
    发明授权
    Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal 有权
    用于向哺乳动物递送甘精胰岛素的肝细胞靶向载体

    公开(公告)号：US07871641B2

    公开(公告)日：2011-01-18

    申请号：US11384728

    申请日：2006-03-20

    Applicant: John R. Lau ,  W. Blair Geho

    Inventor： John R. Lau ,  W. Blair Geho

    IPC: A61K9/127

    CPC classification number: A61K9/1271 ,  A61K38/28

    Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in at least one form wherein the glargine insulin has a positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.

    Abstract translation: 本发明涉及包含与水不溶性靶分子复合物相关的甘精胰岛素和甘精胰岛素的混合物的肝细胞靶向组合物，其中所述复合物包含多个连接的单个单元和超分子脂质构建体基质。 甘精胰岛素以至少一种形式存在于复合物内，其中甘精胰岛素具有与复合物上的负电荷相互作用的正电荷。 本发明还包括用于制备I型和II型糖尿病个体的血糖水平组合物和方法的方法。

    Orally bioavailable lipid-based constructs
    6.
    发明申请
    Orally bioavailable lipid-based constructs 有权
    口服生物可利用的基于脂质的构建体

    公开(公告)号：US20090087479A1

    公开(公告)日：2009-04-02

    申请号：US11904937

    申请日：2007-09-28

    Applicant: John R. Lau ,  W. Blair Geho

    Inventor： John R. Lau ,  W. Blair Geho

    IPC: A61K9/127 ,  A61K38/28 ,  A61P3/00

    CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K31/4045 ,  A61K38/21 ,  A61K38/23 ,  A61K38/28 ,  A61K47/24

    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

    Abstract translation: 本发明通过能够通过消化道的环境与典型的非口服可用的治疗剂或诊断剂分娩使得治疗药物或诊断剂是生物可利用的组合物来实现的。 组合物可以或不可以靶向特定的细胞受体，例如肝细胞。 治疗剂包括但不限于胰岛素，降钙素，5-羟色胺和其它蛋白质。 用生物素或金属靶向剂完成靶向。

    Gelcores
    8.
    发明授权
    Gelcores 失效
    凝胶

    公开(公告)号：US4740375A

    公开(公告)日：1988-04-26

    申请号：US705023

    申请日：1985-02-25

    Applicant: W. Blair Geho ,  John R. Lau

    Inventor： W. Blair Geho ,  John R. Lau

    IPC: A61K9/127 ,  A61K9/50

    CPC classification number: A61K9/1277 ,  Y10S514/801 ,  Y10S514/963 ,  Y10S514/965

    Abstract: This disclosure recognizes the fact that the technology of making vesicles from lecithin and lecithin-like molecules, although well known and highly developed, is associated with problems of instability. It is known that vesicles coalesce, rupture and spill their contents long before the vesicle is used for its intended purpose.It has been discovered and disclosed herein that the deterioration of the vesicle delivery system is due in part to the rupture of the bipolar lipid vesicle membrane by the contents of the core volume or by an external agent. For example, the more detergent-like the properties of the pharmacological agent within the vesicle core volume, the more pronounced will be the attack on the vesicle wall interior. These events in turn will lead to vesicle membrane rupture.This disclosure sets forth the proper manufacturing techniques to achieve vesicle stability following the discovery and also discloses a large-scale experiment which fully establishes the function taking place microscopically in the true vesicle. The experiment designed to substantiate the discovery is one using visible sized dialysis bags to show that gelatinized pharmacological agents are capable of existing without disruption in the appropriate solutions. The dialysis bag could not be used in the administration of a pharmacological agent to a person but illustrates on a large-scale what takes place microscopically in the actual vesicle environment.

    Abstract translation: 该公开内容认识到，虽然众所周知且高度发达的卵磷脂和卵磷脂样分子的制造泡囊的技术与不稳定性的问题相关联。 众所周知，泡囊在使用囊泡的预期目的之前长时间聚结，破裂并溢出其内容物。 本文已经发现和公开了囊泡递送系统的恶化部分是由于双相脂质囊泡膜由核心体积的内容物或外部剂量的破坏引起的。 例如，洗涤剂类似于囊泡体积内的药剂的性质，对泡囊壁内部的攻击将更为显着。 这些事件又会导致囊泡膜破裂。 本公开阐述了在发现之后实现囊泡稳定性的适当制造技术，并且还公开了一种大规模实验，其完全建立了在真实囊泡中显微镜下发挥的功能。 设计用于证实发现的实验是使用可见尺寸的透析袋来显示胶凝化的药理学剂能够在适当的溶液中存在而不中断。 透析袋不能用于向人施用药理剂，而是在实际的泡囊环境中显微镜显示出大量的透析袋。

Patent Agency Ranking